Legal Representation
Attorney
Rosemary S. Tarlton
USPTO Deadlines
Application History
40 events| Date | Code | Type | Description |
|---|---|---|---|
| Jan 26, 2015 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED |
| Jan 26, 2015 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED |
| Jun 26, 2014 | EXRA | O | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED |
| Jun 25, 2014 | EX5G | S | SOU EXTENSION 5 GRANTED |
| Jun 20, 2014 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Jun 20, 2014 | EXT5 | S | SOU EXTENSION 5 FILED |
| Jan 16, 2014 | EXRA | O | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED |
| Jan 15, 2014 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Jan 15, 2014 | EX4G | S | SOU EXTENSION 4 GRANTED |
| Dec 12, 2013 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
| Dec 11, 2013 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Dec 11, 2013 | EXT4 | S | SOU EXTENSION 4 FILED |
| Jul 11, 2013 | EXRA | O | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED |
| Jul 10, 2013 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Jul 9, 2013 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Jun 11, 2013 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Jun 11, 2013 | EXT3 | S | SOU EXTENSION 3 FILED |
| Dec 18, 2012 | EXRA | O | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED |
| Dec 17, 2012 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Dec 17, 2012 | EX2G | S | SOU EXTENSION 2 GRANTED |
| Dec 10, 2012 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Dec 10, 2012 | EXT2 | S | SOU EXTENSION 2 FILED |
| Jun 9, 2012 | EXRA | O | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED |
| Jun 7, 2012 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Jun 7, 2012 | EXT1 | S | SOU EXTENSION 1 FILED |
| Jun 7, 2012 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Dec 20, 2011 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT |
| Oct 25, 2011 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Oct 5, 2011 | NPUB | O | NOTICE OF PUBLICATION |
| Sep 22, 2011 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Sep 21, 2011 | ALIE | A | ASSIGNED TO LIE |
| Sep 8, 2011 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Sep 7, 2011 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Sep 6, 2011 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Sep 6, 2011 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Mar 3, 2011 | CNRT | F | NON-FINAL ACTION MAILED |
| Mar 2, 2011 | DOCK | D | ASSIGNED TO EXAMINER |
| Mar 2, 2011 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Nov 29, 2010 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Nov 25, 2010 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
pharmaceuticals, namely, treatment for central nervous disorders, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; implantable delivery systems comprised of sustainable release drugs for treatment for central nervous disorders and other serious and life-threatening diseases, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"PHARMACEUTICALS"